National Institutes of Health

419 active grants from this agency

235d left D

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

Deadline: Oct 14, 2026
$250,000
235d left D

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Deadline: Oct 14, 2026
Not specified
235d left D

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

Deadline: Oct 14, 2026
Not specified
235d left D

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)

Deadline: Oct 14, 2026
Not specified
235d left D

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)

Deadline: Oct 14, 2026
Not specified
235d left D

Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)

Deadline: Oct 14, 2026
$500,000
235d left D

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)

Deadline: Oct 14, 2026
Not specified
237d left D

CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)

Deadline: Oct 16, 2026
$300,000
240d left D

Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)

Deadline: Oct 19, 2026
$50,000
251d left D

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)

Deadline: Oct 30, 2026
Not specified
254d left D

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)

Deadline: Nov 02, 2026
Not specified
254d left D

Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)

Deadline: Nov 02, 2026
Not specified
257d left D

Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)

Deadline: Nov 05, 2026
Not specified
265d left D

NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)

Deadline: Nov 13, 2026
$350,000
265d left D

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)

Deadline: Nov 13, 2026
$750,000
265d left D

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

Deadline: Nov 13, 2026
$350,000
265d left D

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

Deadline: Nov 13, 2026
$1,050,000
268d left D

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)

Deadline: Nov 16, 2026
$50,000
269d left D

Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

Deadline: Nov 17, 2026
Not specified
269d left D

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

Deadline: Nov 17, 2026
Not specified
269d left D

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

Deadline: Nov 17, 2026
Not specified
269d left D

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

Deadline: Nov 17, 2026
$350,000
270d left D

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)

Deadline: Nov 18, 2026
Not specified
270d left D

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)

Deadline: Nov 18, 2026
Not specified
271d left D

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Deadline: Nov 19, 2026
Not specified